Lung Cancer Therapeutics Market By Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Others), By Disease Type (Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC)), By Geography, Size, Share, Global Industry Report, Forecast, 2021-2030

Industry Report and Statistics (Facts & Figures) - Number of Procedue, Sales Volume & ASP by Therapy Type & Diseases

The global lung cancer therapeutics market will witness a robust CAGR of 8.74%, valued at $28.56 billion in 2021, expected to appreciate and reach $60.72 billion by 2030, confirms Strategic Market Research. North America is destined to dominate the overall market share, followed by Europe. Lung cancer is a type of cancer that develops in the tissues of the lungs, most commonly in the cells lining the airways. Lung cancer is the most common cancer-related death worldwide. Lung cancer signs and symptoms may include Persistent Cough, Shortness of Breath, Body Pain (Chest, Back and Shoulders), Repeated Respiratory Infections, Fatigue, Blood clots and unexpected Weight loss. According to GLOBOCAN 2020, Lung cancer was the second most often diagnosed cancer and the main cause of cancer mortality in 2020, with an expected 2.2 million new cases and 1.8 million fatalities, accounting for around one in every ten (11.4%) cancer diagnoses and one in every five (18.0%) deaths.

 

 

Types: Lung cancer is divided into two categories. The below-mentioned types grow differently and are treated differently. Non-small cell lung cancer is the more prominent and frequent type.

 

Small cell lung cancer (SCLC)

Small cell lung cancer is a condition in which malignant (cancer) cells originate in lung tissues. It initially targets the breathing tubes (bronchi) in the middle of the chest. Small cell lung cancer is most commonly caused by smoking. SCLS is the deadliest among both types of lung cancers. SCLC patients have a 7% survival rate (5 years). Although cancer cells are tiny, they proliferate swiftly and form enormous tumours. According to an article published in NCBI, Small-cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma (solid tumour) that accounts for approximately 10–15 % of all lung cancer cases. Radiation and chemotherapy are frequently used to treat SCLC.

 

Non-small cell lung cancer (NSCLC)

NSCLC starts at the cellular level, causing malignant lung cells to reproduce rapidly and uncontrollably. It usually arises in the outer region of the Lungs, and it is more frequent in women. After the diagnosis of NSCLC, the stage of cancer is determined. Smoking is the most common cause (around 90%) of non-small cell lung cancer. NSCLC patients have a 63% survival rate (5 years). Patients can use combinations of surgery, chemotherapy, radiation therapy, and targeted therapy to treat NSCLC.

 

Stages in Lung Cancer - Staging Describes the Size, Extent and Spread of Cancer.

• Stage 1: Tumour is less than 3cm. There is no metastasis (spreading)

• Stage 2: Tumour is less than 6cm. Single metastasis (spread from one tumour) is observed.

• Stage 3: Tumour is more than 6cm. Metastasis is seen in lymph nodes

• Stage 4: Tumour passes to other organs.

 

Cure - Treatment Options Available for Lung Cancer are:

• Surgery: The malignant tissue is removed in this procedure.

• Radiation therapy: Using high-energy rays (similar to X-rays) to kill cancer.

• Chemotherapy: Uses powerful chemicals (drugs) to kill fast-growing cells in the body. 

• Targeted therapy: Uses Medications to prevent cancer cells from growing and spreading.

• Immunotherapy: Uses a person's immune system to fight cancer. 

 

 

Key Market Dynamics

Prominent Drivers (Unhealthy Lifestyles, Demand for Targeted Therapies, Presence of Highly Efficient Drugs, High Incidence rate and Rising Pollution)

 

Key Factors that Promote the Growth of the Industry:

Unhealthy Lifestyles

The increase in the adoption of unhealthy lifestyles, such as smoking, is one of the key factors propelling the overall growth rate of the lung cancer therapeutics market. Cigarette smoking is known to be the most important cause of lung cancer. The findings in the Global Burden of Disease Study (GBD 2019) estimate that tobacco use (8.7 million), smoking (7.7 million) and second-hand smoke (1.3 million) account for nearly 18 million deaths every year.

 

Demand for Targeted Therapies

The demand for targeted therapies, which include chemotherapy, immunotherapy, surgery, and radiation therapy to treat and cure lung cancer, propels the industry's growth. Targeted therapy is becoming increasingly popular as a cancer treatment option since it is far more effective than chemotherapy. While chemotherapy has a success rate of roughly 30%, targeted therapy has an 80% success rate.

 

Presence of Highly Efficient Drugs

Until recently, conventional treatment options for lung cancer included surgery, chemotherapy, and radiation. Recent clinical studies treating patients with immunotherapy, either alone or with other treatments, have demonstrated significant patient improvement. Highly efficient drugs, such as Avastin, Tarceva, Taxotere and Gemzar are further driving the market.

 

High Incidence rate

Lung cancer ranks second in the most frequent cancer in the US, and it is also the deadliest, causing the most deaths of all cancers. According to the American Cancer Society, Lung cancer is now the most common cause of cancer death, responsible for over 25% of cancer deaths.

 

Rising Pollution Levels:

The increasing incidence of Heart disease and strokes, lung cancer, lower respiratory infections, diabetes, and chronic obstructive pulmonary disease (COPD) is directly correlated to air pollution (outdoor and indoor particulate matter and ozone). Air pollution is third among the world's main reasons for mortality, according to the Global Burden of Disease study report (2019). Air pollution led to 6.82 million annual fatalities globally, with indoor air pollution accounting for 33% and outdoor air pollution at 66%.

 

Restraints - Regional Disparities in Treatment and its Side-effects

• Regional disparities in treatment: The most common reason for cancer death worldwide is lung cancer, the burden of which is felt heavily in lower- and middle-income countries (LMICs), where early and prompt detection and treatment are limited. According to the findings of WHO, only about 30% of cancer patients in low-income nations have access to therapy, compared to 90% in high-income countries. Nearly two-thirds of the global population over the age of 60 will reside in low- and middle-income nations by 2050.

 

• Side effects: Chemotherapy can have unpleasant side effects, but most can be controlled or avoided, and the majority go away once the treatment is finished. The side effects include low blood cell counts, Tiredness (fatigue), Nausea, Hair loss, Infection, Anaemia, Loss of Appetite, Memory, sleep and concentration problems.

 

Opportunities 

• The arrival of nanomedicine to treat lung cancer: Researchers have asserted that nanotechnology-based inhalation chemotherapy is highly effective than conventional chemotherapy, containing less number of side effects. A myriad number of nanocarriers have been investigated, which include liposomes, micelles, polymeric NPs, inorganic NPs and solid lipid NPs, for inhalation treatment of lung cancer. Recently, an effective and promising approach for lung cancer treatment published in Advanced Therapeutics combines a novel surgical approach with smart nanoparticles to target lung tumours. 

 

• Growing approvals in lung cancer therapeutics: The development and approval of new cancer therapies during the past decade have led the modern era of cancer treatment to be referred to as the golden age of oncology. According to the FDA's press announcements, the US Food and Drug Administration approved more than 95 drugs for Lung Cancer, including immunotherapies, targeted drugs, and chemotherapies. The last decade witnessed the highest approvals so far as compared to the approvals in eight decades.

 

• Increase in fund allocations for R&D of New Drugs: Due to investments in research through the National Cancer Institute (NCI), rates of new cancers are declining. NCI is the oldest and has the largest budget and research program of the 27 institutes and centres of the NIH (National Institutes of Health). According to National Cancer Institute's Budget Fact Book 2020, the annual funds available to the NCI totalled $6.1, reflecting an increase of 3%, or $178 million from the previous fiscal year.

  

Lung Cancer Therapeutics Market Analysis Of Different Segments Covered in the Report

Based on Therapy

• Chemotherapy

• Radiation Therapy

• Immunotherapy

• Targeted Therapy

• Others

 

Based on Type

• Small Cell Lung Cancer (SCLC)

• Non-Small Cell Lung Cancer (NSCLC)

 

Regional Coverage Analysis

• North America

• Asia-Pacific

• Europe

• Latin America

• The Middle East and Africa

 

Segments Analysis & Insights

By Therapy, Chemotherapy dominates the industry share. Anti-cancer (cytotoxic) medicines are used in chemotherapy to kill cancer cells. These work by disrupting the growth of cancer cells. Chemotherapy is commonly used to treat cancer because cancer cells grow and proliferate significantly faster than the rest of the body's cells. Patients can use chemotherapy medications alone or in combination.

 

By Disease Type, Non-Small Cell Lung Cancer captures the lion's share in the market. NSCLC is the most common of the two types of lung cancer. There are three main subtypes of non-small cell lung cancer (NSCLC): Squamous cell carcinoma (25% of lung cancers), Adenocarcinoma (40% of lung cancers) and Large cell carcinoma (10% of lung cancers). As per the American Cancer Society 2019, about 80% to 85% of lung cancers are NSCLC. At the same time, SCLC is responsible for 10% to 15% of cases.

 

Based on Region, North America is expected to lead the global lung cancer therapeutics market share due to the increasing number of patients with lung cancer. There is an increasing trend and adoption of advanced therapeutics in North America, Latin America, the Middle East, and Africa. However, there is a high inclination towards chemotherapy in the Asia Pacific. According to GLOBOCAN 2020, Lung cancer is the leading cause of cancer morbidity and mortality in men, whereas, in women, it ranks third for incidence after breast and colorectal cancer. North America has one of the highest age-standardized incidence rates (35.7 Males and 30.1 Females)

 

Lung Cancer Therapeutics Market Report Coverage

Report Attribute	Details
Forecast Period	2021 - 2030
The market size value in 2021	USD 28.56 Billion
The revenue forecast in 2030	USD  60.72 Billion
Growth rate	CAGR of 8.74%
The base year for estimation	2021
Historical data	2017 – 2020
Unit	USD Billion, CAGR (2021 - 2030)
Segmentation	By Therapy, Disease Type and Region.
By Therapy	Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy and Others
By Disease Type	Small Cell Lung Cancers &  Non-Small Cell Lung Cancers
By Region	North America, Europe, Asia-Pacific, Latin America the Middle East and Africa.
Country Scope	US, Mexico, Canada, Germany, UK, France, China, Japan, India etc.
Company Usability Profiles	AstraZeneca, Boehringer- Ingelheim, Merck, CIRS, PharmaMar SA, Bristol-Myers Squibb Company, PharmaMar, SA, Novartis AG and Eli Lilly

 

Global Lung Cancer Therapeutics Market Competitive Landscape Analysis

The report has covered a detailed competitor analysis, which outlines the most significant competitors operating worldwide. Overall revenue generation, SWOT Analysis, market initiatives, company overview, Seed investments by venture capitalists, R&D investment, production analysis, value chain optimization, company strengths and weaknesses, global presence, manufacturing capacity, value chain analysis, market potential, porter’s five force analysis and various other factors are used to have a thorough understanding of different players and their key market strategies.

 

• AstraZeneca

• Boehringer Ingelheim

• Bristol-Myers Squibb Company

• Novartis AG

• Merck

• PharmaMar SA

• Eli Lilly and Company

 

 Recent Developments in the industry:

• In May 2022, Cizzle Biotechnology, a diagnostics company based in the United Kingdom, inked a deal with CorePath Laboratories ("CorePath"), a full-service cancer reference laboratory, to develop and market its patented early-stage lung cancer test in the United States. There are currently no simple specialized blood tests for early detection of lung cancer where targeted treatments could enhance timely access to cancer care and save lives. However, it is estimated that over 8 million Americans are at high risk for lung cancer and should be checked annually with low-dose CT scans. A proper examination can avoid over 24,000 lung cancer deaths.

 

• In April 2022, In conjunction with Eli Lilly and Company, NeoGenomics, Inc., which is the most prominent provider of oncology contract research services and cancer-focused genetic testing services, made an announcement of a sponsored testing programme for qualifying patients having metastatic non-small cell lung cancer (NSCLC) absolutely free of cost. The NeoTYPE DNA and RNA Assay will be used by Lilly Lung Cancer Sponsored Testing Program to grant qualifying metastatic NSCLC patients improved access to focused genomic test solutions that can assist patients and physicians in making educated treatment decisions. Eligible patients can use InVisionFirst-Lung Liquid Biopsy at no cost if findings aren't possible due to decreased tissue input or when an invasive biopsy is prohibited medically.

 

• In April 2022, the European Medicines Agency validated Marketing Authorization Applications (MAAs) for tislelizumab in several non-small cell lung cancer and oesophagal squamous cell carcinoma indications. Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody that is researched as a single therapy and in combination with other treatments. Submissions based on data from the RATIONALE 302, 303, 304, and 307 Phase III trials, in which tislelizumab monotherapy and chemotherapy combined showed significant clinical improvements over chemotherapy in a variety of cancer types and treatment lines.

 

• In May 2021,  Lumakras (sotorasib) was approved by US FDA as the first line of treatment for grown-up patients possessing non-small cell lung cancer who have had at least one systemic therapy beforehand and whose tumours have a KRAS mutation (G12C). Lumakras was the first targeted therapy approved for tumours consisting of any sort of KRAS mutation, which sums up to around twenty-five percent of mutations present in the cases of non-small cell lung cancers. The KRAS G12C mutations make up about a third of all non-small cell lung cancer mutations.

 

• In October 2020, the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC), Guardant Health along with AstraZeneca, the four founding partners of Lung Ambition Alliance (LAA), added five additional project partners, bolstering this unique alliance with the audacious goal of eradicating lung cancer as a cause of death. Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Merck, and Novartis have joined the Lung Ambition Alliance as project partners.

 

Various Products that Key Players Develop:

Product	Function	Key players
Keytruda	The immuno-oncology drug for treating first- and second-line non-small cell lung cancer (NSCLC).	Merck
Tagrisso (osimertinib)	For early-stage epidermal growth factor receptor-mutated (EGFRm) and non-small cell lung cancer (NSCLC) after tumour resection with curative intent.	AstraZeneca
ZEPZELCA (lurbinectedin)	For treatment of metastatic SCLC.	PharmaMar SA
002LFC IMRT Thorax Phantom	Used as equipment for radiation therapy to treat lung and thorax cancer.	CIRS